{"transactions":[{"id":795847,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2026-05-01T22:26:58.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":4060259,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":211013},"source":{"system":"sec-edgar","filing":"0001193125-26-201863","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1903360/000119312526201863/ownership.xml","form_type":"4"}},{"id":795846,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Convertible Preferred Stock","published_at":"2026-05-01T22:26:58.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":20482289,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1064473},"source":{"system":"sec-edgar","filing":"0001193125-26-201863","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1903360/000119312526201863/ownership.xml","form_type":"4"}},{"id":795845,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-01T22:26:58.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":1275486,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date."}],"balance_after":1275486,"source":{"system":"sec-edgar","filing":"0001193125-26-201863","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1903360/000119312526201863/ownership.xml","form_type":"4"}},{"id":1287644,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2025-02-03T18:48:52.000Z","date":"2025-01-30","kind":"exercise","planned":false,"acquired":false,"shares":4365079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1857699},"source":{"system":"sec-edgar","filing":"0000950170-25-012574","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012574/ownership.xml","form_type":"4"}},{"id":1287643,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T18:48:52.000Z","date":"2025-01-30","kind":"exercise","planned":false,"acquired":true,"shares":1857699,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":1857699,"source":{"system":"sec-edgar","filing":"0000950170-25-012574","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012574/ownership.xml","form_type":"4"}},{"id":1386806,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B redeemable convertible preferred stock","published_at":"2024-10-15T23:21:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":852940,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":894733},"source":{"system":"sec-edgar","filing":"0000950170-24-114802","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000095017024114802/ownership.xml","form_type":"4"}},{"id":1386805,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T23:21:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":894733,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date."}],"balance_after":894733,"source":{"system":"sec-edgar","filing":"0000950170-24-114802","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000095017024114802/ownership.xml","form_type":"4"}},{"id":1405426,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2024-09-17T23:15:36.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":4854368,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":403787},"source":{"system":"sec-edgar","filing":"0000950170-24-107489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1903360/000095017024107489/ownership.xml","form_type":"4"}},{"id":1405425,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-09-17T23:15:36.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":16666666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1386335},"source":{"system":"sec-edgar","filing":"0000950170-24-107489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1903360/000095017024107489/ownership.xml","form_type":"4"}},{"id":1405424,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T23:15:36.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":403787,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date."}],"balance_after":1790122,"source":{"system":"sec-edgar","filing":"0000950170-24-107489","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1903360/000095017024107489/ownership.xml","form_type":"4"}},{"id":1405423,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T23:15:36.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":1386335,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date."}],"balance_after":1386335,"source":{"system":"sec-edgar","filing":"0000950170-24-107489","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1903360/000095017024107489/ownership.xml","form_type":"4"}},{"id":1739375,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2023-11-16T21:19:24.000Z","date":"2023-11-14","kind":"exercise","planned":false,"acquired":false,"shares":10000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737000},"source":{"system":"sec-edgar","filing":"0000950170-23-064519","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1903360/000095017023064519/ownership.xml","form_type":"4"}},{"id":1739374,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-16T21:19:24.000Z","date":"2023-11-14","kind":"exercise","planned":false,"acquired":true,"shares":737000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date."}],"balance_after":737000,"source":{"system":"sec-edgar","filing":"0000950170-23-064519","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1903360/000095017023064519/ownership.xml","form_type":"4"}},{"id":1777711,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2023-09-19T23:41:36.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":1557846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1557846},"source":{"system":"sec-edgar","filing":"0000950170-23-048874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1903360/000095017023048874/ownership.xml","form_type":"4"}},{"id":1777710,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":50328,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","position":1,"cik":"0001903360","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-19T23:41:36.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":1557846,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date."}],"balance_after":1557846,"source":{"system":"sec-edgar","filing":"0000950170-23-048874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1903360/000095017023048874/ownership.xml","form_type":"4"}}]}